The Analysis Study of Effects of Glucagon-Like Peptide-1 Receptor to Reduce Adverse Cardiovascular Events in Patients with Type 2 Diabetes Mellitus: A Comprehensive Systematic Review
Keywords:
Type 2 Diabetes mellitus, cardiovascular, glucagon-like peptide-1 receptorAbstract
Background: The aim of this study to show about effects of glucagon-like peptide-1 receptor to reduce adverse cardiovascular events in patients with type 2 diabetes mellitus. Methods: By the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) 2020, this study was able to show that it met all of the requirements. Result: Eight publications were found to be directly related to our ongoing systematic examination after a rigorous three-level screening approach. Subsequently, a comprehensive analysis of the complete text was conducted, and additional scrutiny was given to these articles. Conclusion: GLP‐1 receptor agonists represent a relatively new class of drugs used for the treatment of T2DM. They are not only able to improve hyperglycaemia of diabetic patients but also directly influence in addition other significant risk factors for CVD such as high blood pressure, dyslipidaemia or obesity. These properties explain at least in part the positive results of the CV outcome studies for liraglutide, semaglutide, dulaglutide and albiglutide, all of which showed not only CV safety but also an improvement in CV prognosis.
References
Nachawi N, Rao PP, Makin V. The role of GLP-1 receptor agonists in managing type 2 diabetes. Cleve Clin J Med. 2022;89(8):457–64.
Hinnen D. Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes. Diabetes Spectr [Internet]. 2017 Aug 1;30(3):202–10. Available from: https://diabetesjournals.org/spectrum/article/30/3/202/32399/Glucagon-Like-Peptide-1-Receptor-Agonists-for-Type
Collins L, Costello RA. Glucagon-Like Peptide-1 Receptor Agonists [Internet]. StatPearls. 2024. Available from: http://www.ncbi.nlm.nih.gov/pubmed/31641522
Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834–44.
Rivera FB, Cruz LLA, Magalong JV, Ruyeras JMMJ, Aparece JP, Bantayan NRB, et al. Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: A meta-analysis of randomized placebo-controlled trials. Am J Prev Cardiol [Internet]. 2024;18(March):100679. Available from: https://doi.org/10.1016/j.ajpc.2024.100679
Ferhatbegović L, Mršić D, Macić-Džanković A. The benefits of GLP1 receptors in cardiovascular diseases. Front Clin Diabetes Healthc. 2023;4(December):1–8.
Qiu M, Ding L, Wei X, Wei W, Zhou H. Effects of glucagon-like peptide 1 receptor agonists and sodium glucose cotransporter 2 inhibitors on major adverse cardiovascular events in type 2 diabetes by race, ethnicity, and region: A meta-analysis. Med (United States). 2020;99(49):1–9.
Simms-Williams N, Treves N, Yin H, Lu S, Yu O, Pradhan R, et al. Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: Population based cohort study. Bmj. 2024;
Guo X, Sang C, Tang R, Jiang C, Li S, Liu N, et al. Effects of glucagon-like peptide-1 receptor agonists on major coronary events in patients with type 2 diabetes. Diabetes, Obes Metab. 2023;25(S1):53–63.
Kim GS, Park JH, Won JC. The role of glucagon-like peptide 1 receptor agonists and sodium-glucose cotransporter 2 inhibitors in reducing cardiovascular events in patients with type 2 diabetes. Endocrinol Metab. 2019;34(2):106–16.
Wester A, Shang Y, Toresson Grip E, Matthews AA, Hagström H. Glucagon-like peptide-1 receptor agonists and risk of major adverse liver outcomes in patients with chronic liver disease and type 2 diabetes. Gut. 2024;73(5):835–43.
Yen FS, Hou MC, Wei JCC, Shih YH, Hwu CM, Hsu CC. Effects of glucagon-like peptide-1 receptor agonists on liver-related and cardiovascular mortality in patients with type 2 diabetes. BMC Med [Internet]. 2024;22(1):1–9. Available from: https://doi.org/10.1186/s12916-023-03228-4
Lin Y, Wang TH, Tsai ML, Wu VCC, Tseng CJ, Lin MS, et al. The cardiovascular and renal effects of glucagon-like peptide 1 receptor agonists in patients with advanced diabetic kidney disease. Cardiovasc Diabetol [Internet]. 2023;22(1):1–11. Available from: https://doi.org/10.1186/s12933-023-01793-9
Pan HC, Chen JY, Chen HY, Yeh FY, Sun CY, Huang TTM, et al. GLP-1 receptor agonists’ impact on cardio-renal outcomes and mortality in T2D with acute kidney disease. Nat Commun [Internet]. 2024;15(1). Available from: http://dx.doi.org/10.1038/s41467-024-50199-y
Stenberg E, Näslund E. Major adverse cardiovascular events among patients with type-2 diabetes, a nationwide cohort study comparing primary metabolic and bariatric surgery to GLP-1 receptor agonist treatment. Int J Obes. 2023;47(4):251–6.
Trevisan M, Fu EL, Szummer K, Norhammar A, Lundman P, Wanner C, et al. Glucagon-like peptide-1 receptor agonists and the risk of cardiovascular events in diabetes patients surviving an acute myocardial infarction. Eur Hear J - Cardiovasc Pharmacother. 2021;7(2):104–11.
Wang L, Xu R, Kaelber DC, Berger NA. Glucagon-Like Peptide 1 Receptor Agonists and 13 Obesity-Associated Cancers in Patients with Type 2 Diabetes. JAMA Netw Open. 2024;7(7):e2421305.
Gourdy P, Darmon P, Dievart F, Halimi JM, Guerci B. Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM). Cardiovasc Diabetol [Internet]. 2023;22(1):1–14. Available from: https://doi.org/10.1186/s12933-023-01798-4
Marsico F, Paolillo S, Gargiulo P, Bruzzese D, Dell’Aversana S, Esposito I, et al. Effects of glucagon-like peptide-1 receptor agonists on major cardiovascular events in patients with Type 2 diabetes mellitus with or without established cardiovascular disease: A meta-analysis of randomized controlled trials. Eur Heart J. 2020;41(35):3346–58.
Parab P, Chaudhary P, Mukhtar S, Moradi A, Kodali A, Okoye C, et al. Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Cardiovascular Risk Management in Patients With Type 2 Diabetes Mellitus: A Systematic Review. Cureus. 2023;1(December 2008):1–11.
Hosseinpour A, Sood A, Kamalpour J, Zandi E, Pakmehr SA, Hosseinpour H, et al. Glucagon-Like Peptide-1 Receptor Agonists and Major Adverse Cardiovascular Events in Patients With and Without Diabetes: A Meta-Analysis of Randomized-Controlled Trials. Clin Cardiol. 2024;47(7).
Macisaac RJ. Glucagon-like peptide-1 receptor agonists and the cardiorenal axis in Type 2 diabetes: a focus on dulaglutide. Future Cardiol. 2021;17(3):459–73.
Qin J, Song L. Glucagon-like peptide-1 (GLP-1) receptor agonists and cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of double-blind, randomized, placebo-controlled clinical trials. BMC Endocr Disord [Internet]. 2022;22(1):1–7. Available from: https://doi.org/10.1186/s12902-022-01036-0
Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Furtado RHM, et al. Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus: Systematic review and meta-analysis of cardiovascular outcomes trials. Circulation. 2019;139(17):2022–31.
Helmstädter J, Keppeler K, Küster L, Münzel T, Daiber A, Steven S. Glucagon-like peptide-1 (GLP-1) receptor agonists and their cardiovascular benefits—The role of the GLP-1 receptor. Br J Pharmacol. 2022;179(4):659–76.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Radian Tommy Firmansyah, Lydia Nur Amalia (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors publishing here keep copyright but grant the journal first publication rights, under a Creative Commons Attribution-NonCommercial 4.0 License. They can distribute their work non-exclusively elsewhere with an acknowledgment of its first publication in this journal. Posting the work online before and during submission for earlier and greater citation is encouraged, reflecting Open Access benefits.
